PRICE HISTORY.
Use the left and right arrow keys to inspect dated observations. Home selects the first observation and End selects the latest.
Key numbers
Published fundamentals and the date each figure was recorded.
Sigachi Laboratories Limited is a listed company whose 2024-25 annual report describes it as engaged in manufacturing bulk drugs or drug intermediates. Its registered office and Unit I are at Bonthapally, Telangana; the report identifies a second factory at Ali Nagar. The issuer’s financial statements record revenue from operations and other income, and the directors’ report states that the company leased its two factories from 1 May 2025 for 15 years after receiving approvals. The report also states that the company provides demand loans or inter-corporate deposits to parties and receives interest, with no overdue loans or inter-corporate deposits reported by management. The company’s securities are listed on the Metropolitan Stock Exchange of India Limited. The audited financial statements use Ind AS and were approved by the board on 29 May 2025. This is a factual description of the business configuration stated in the latest annual report; it does not characterize current operational scale or make a forecast.
About this company
Sigachi Laboratories Limited is a Telangana-based pharmaceutical manufacturer incorporated in 1994, operating in the bulk drugs and drug intermediates space. The company produces active pharmaceutical ingredients and intermediate chemical compounds that serve as the building blocks for finished formulations, supplying these inputs to the broader pharmaceutical and chemical manufacturing chain. Its operations are anchored at facilities in the Bonthapally industrial belt of Sangareddy district, a region that has long been a hub for India's bulk-drug and API production. Beyond its core manufacturing income, the company's reported revenue also reflects earnings from interest on loans, inter-corporate deposits, and fixed deposits, indicating a treasury component alongside its industrial activity. With a face value of ₹10 per share and a relatively concentrated equity base of roughly 6.75 million shares, it is a small-capitalisation enterprise by Indian standards. A notable point of distinction is that Sigachi Laboratories Limited is a separate legal entity from the NSE- and BSE-listed Sigachi Industries Limited, despite the shared "Sigachi" name and a common heritage in the pharmaceutical sector. Sigachi Laboratories is admitted on the Metropolitan Stock Exchange of India (MSEI), a regional exchange with limited active trading, and it does not trade on the NSE or BSE main boards. As a result, its shares are commonly transacted in the over-the-counter unlisted market. This combination of attributes is what draws attention to the company in the unlisted segment. Investors and market participants tracking pharmaceutical and API names often monitor such MSEI-admitted, thinly traded companies because they sit outside mainstream exchange coverage. The shares are dematerialised through NSDL and CDSL, which supports off-market transfers. Reported book value per share has historically run above the face value, reflecting accumulated reserves. As with all unlisted securities, available information is less standardised than for actively listed peers, and the indicative price reflects negotiated private-market dealing rather than continuous exchange-driven price discovery.
COMPANY REGISTRY · ON FILE
THE CREW · BOARD & MANAGEMENT
COMMON QUESTIONS.
Is Sigachi Laboratories Limited listed on the stock exchange?+
No. As of 2 September 2026, Sigachi Laboratories Limited is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
What is the Sigachi Laboratories Limited unlisted share price?+
As of 2 September 2026, the indicative unlisted share price of Sigachi Laboratories Limited is ₹52 per share. This is an over-the-counter reference price, not a stock-exchange quote.
What indicative minimum amount is displayed for Sigachi Laboratories Limited unlisted shares?+
The displayed unit count is 195 share(s); at the indicative price of about ₹52, the displayed amount is approximately ₹10,140. This is a display convention, not evidence of inventory, an order minimum or a quote.
What is the ISIN of Sigachi Laboratories Limited?+
The recorded ISIN of Sigachi Laboratories Limited is INE368H01018. An ISIN is a 12-character security identifier. Verify it against the issuer and the relevant depository record before using it for any transfer or documentation.
Is trading in Sigachi Laboratories Limited unlisted shares legal in India?+
Unlisted shares can be transferred off-market in India, but the legal, tax and compliance position depends on the security, parties, documents and current rules. Verify the intermediary, issuer restrictions and applicable requirements before proceeding.
Is there a lock-in period for unlisted shares?+
A post-listing lock-in may apply under the rules in force at the time. The period and any exemptions can depend on the holder and acquisition, so check the current regulation and the issuer's offer documents rather than relying on a generic period.
Do you guarantee returns?+
No. Unlisted shares carry higher risk and lower liquidity than listed shares. Returns depend on company performance, market conditions and future listing outcomes. This is information only, not investment advice.